Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
HOOK Stock Forecast 2026-2027
$0.84
Current Price
$11.01M
Market Cap
Buy 0
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to HOOK Price Targets
N/A
To High Target of $N/A
N/A
To Median Target of $N/A
N/A
To Low Target of $N/A
HOOK Price Momentum
0.0%
1 Week Change
0.0%
1 Month Change
-26.3%
1 Year Change
0.0%
Year-to-Date Change
-85.2%
From 52W High of $5.66
+16.5%
From 52W Low of $0.72
📊 TOP ANALYST CALLS
Did HOOK Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Hookipa Pharma is one of their latest high-conviction picks.
Latest HOOK Stock Price Targets & Analyst Predictions
HOOK has shown a year-to-date change of 0.0% and a 1-year change of -26.3%, reflecting downward momentum over the past year. Comprehensive analyst forecasts are currently unavailable for HOOK. Please refer to the price chart above for recent performance and trends.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
HOOK Analyst Ratings
0
Buy
1
Hold
0
Sell
HOOK Price Target Range
Low
N/A
Average
N/A
High
N/A
Current: $0.84
Latest HOOK Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for HOOK.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 10, 2025 | HC Wainwright & Co. | Arthur He | Neutral | Downgrade | $N/A |
| Dec 20, 2024 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $2.00 |
| Nov 21, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $7.00 |
| Nov 15, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $48.00 |
| Aug 9, 2024 | JMP Securities | Roy Buchanan | Market Outperform | Maintains | $24.00 |
| Jul 26, 2024 | JMP Securities | Jason Butler | Market Outperform | Maintains | $23.00 |
| Jun 5, 2024 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $6.00 |
| May 21, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $5.00 |
| Apr 26, 2024 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $5.00 |
| Mar 25, 2024 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $5.00 |
| Mar 25, 2024 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $6.50 |
| Jan 30, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $5.00 |
| Sep 27, 2023 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $7.00 |
| Sep 6, 2023 | Truist Securities | Asthika Goonewardene | Buy | Reiterates | $4.00 |
| Aug 11, 2023 | HC Wainwright & Co. | Arthur He | Buy | Maintains | $6.50 |
| Jun 30, 2023 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $7.00 |
| Jun 5, 2023 | Morgan Stanley | Equal-Weight | Maintains | $N/A | |
| May 12, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $8.00 |
| Mar 20, 2023 | Truist Securities | Asthika Goonewardene | Buy | Maintains | $4.00 |
| Mar 16, 2023 | HC Wainwright & Co. | Arthur He | Buy | Reiterates | $8.00 |
Hookipa Pharma Inc. (HOOK) Competitors
The following stocks are similar to Hookipa Pharma based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
HOOK
Hookipa Pharma
mkt cap
11.01M
Hookipa Pharma Inc. (HOOK) Financial Data
Hookipa Pharma Inc. has a market capitalization of $11.01M with a P/E ratio of -0.2x. The company generates $9.35M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is -94.5% quarter-over-quarter, while maintaining an operating margin of -885.3% and return on equity of -105.8%.
Valuation Metrics
Market Cap
$11.01M
Enterprise Value
$-28,021,764
P/E Ratio
-0.2x
PEG Ratio
-0.2x
Price/Sales
1.2x
Growth & Margins
Revenue Growth (YoY)
-94.5%
Gross Margin
N/A
Operating Margin
-885.3%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+378.3%
Current Ratio
3.6x
Debt/Equity
1.7x
ROE
-105.8%
ROA
-45.2%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Hookipa Pharma Inc. (HOOK) Business Model
About Hookipa Pharma Inc.
What They Do
Develops innovative immunotherapies for diseases.
Business Model
Hookipa Pharma Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of immunotherapies using its proprietary arenavirus platform. The company generates revenue by advancing its vaccine candidates through clinical trials, aiming to secure partnerships or licensing agreements with larger pharmaceutical companies interested in its innovative products.
Additional Information
Based in New York City, Hookipa Pharma targets high-need areas in oncology and infectious diseases, emphasizing the creation of treatments that offer improved efficacy and fewer side effects than traditional options. The company's research and development efforts are positioned to have a significant impact on public health, making it an appealing investment for those interested in biopharmaceutical advancements.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
82
CEO
Dr. Malte Peters M.D.
Country
United States
IPO Year
2019
Website
www.hookipapharma.comHookipa Pharma Inc. (HOOK) Latest News & Analysis
Latest News
Quick Summary
NeoTrail Therapeutics has acquired next-generation therapeutic cancer vaccines in development for various oncology indications, with the purchase price not disclosed.
Why It Matters
The sale of next-gen cancer vaccines to NeoTrail Therapeutics indicates strong advancements in oncology, potentially enhancing market competitiveness and driving investor interest in biotech.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
HOOKIPA Pharma Inc. completed the sale of its HB-400 and certain HB-500 program assets to Gilead Sciences, Inc. on October 31, 2025.
Why It Matters
The asset sale to Gilead may enhance HOOKIPA's financial position, shift focus to other projects, and influence stock performance and investor sentiment towards both companies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HOOKIPA Pharma Announces Intention to Voluntarily Delist and Deregister its Common Stock
11 months ago
Quick Summary
HOOKIPA Pharma Inc. plans to voluntarily delist from Nasdaq and deregister its common stock, suspending reporting obligations under the Securities Exchange Act.
Why It Matters
HOOKIPA Pharma's delisting from Nasdaq may reduce liquidity and transparency, impacting stock value and investor confidence in its future funding and development prospects.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A notice from New York and Vienna warns against the release, publication, or distribution of certain information in jurisdictions where it may violate local laws.
Why It Matters
The announcement indicates legal restrictions on the distribution of information, which may affect market perceptions and trading strategies related to the involved parties.
Source: GlobeNewsWire
Market Sentiment:
Neutral
HOOKIPA Pharma Inc - FORM 8 (OPD)
1 year ago
Quick Summary
HOOKIPA Pharma Inc. disclosed a public opening position under the Takeover Code, indicating ownership interests and short positions as required by regulations.
Why It Matters
HOOKIPA Pharma's disclosure under the Takeover Code signals potential corporate activity, like an acquisition or merger, influencing stock volatility and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
The content is restricted and cannot be released or distributed in jurisdictions where it would violate local laws or regulations.
Why It Matters
The excerpt indicates legal restrictions on distribution, signaling potential regulatory risks and compliance issues that could affect investment opportunities and market perception.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About HOOK Stock
What is Hookipa Pharma Inc.'s (HOOK) stock forecast for 2027?
Analyst forecasts for Hookipa Pharma Inc. (HOOK) are not currently available. The stock is trading at $0.84.
Is HOOK stock a good investment in 2027?
According to current analyst ratings, HOOK has 0 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.84. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for HOOK stock?
Price predictions from Wall Street analysts for HOOK are not currently available. The stock is trading at $0.84.
What is Hookipa Pharma Inc.'s business model?
Hookipa Pharma Inc. operates as a clinical-stage biopharmaceutical company, focusing on the development of immunotherapies using its proprietary arenavirus platform. The company generates revenue by advancing its vaccine candidates through clinical trials, aiming to secure partnerships or licensing agreements with larger pharmaceutical companies interested in its innovative products.
What is the highest forecasted price for HOOK Hookipa Pharma Inc.?
Price targets from Wall Street analysts for HOOK are not currently available. The stock is trading at $0.84.
What is the lowest forecasted price for HOOK Hookipa Pharma Inc.?
Price targets from Wall Street analysts for HOOK are not currently available. The stock is trading at $0.84.
What is the overall HOOK consensus from analysts for Hookipa Pharma Inc.?
The overall analyst consensus for HOOK is neutral. Out of 10 Wall Street analysts, 0 rate it as Buy, 1 as Hold, and 0 as Sell.
How accurate are HOOK stock price projections?
Stock price projections, including those for Hookipa Pharma Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 16, 2026 7:30 AM UTC